In this issue:
- Is survival in MM improved in clinical trials?
- Epidemiological landscape of MM diagnosed before age 40 years
- MCT1 as a predictor for lenalidomide maintenance in MM
- KRd/KCd + autologous SCT or KRd alone, followed by lenalidomide ±carfilzomib, in newly diagnosed MM
- KRd then lenalidomide maintenance for preventing smouldering myeloma progression
- Ixazomib vs. pomalidomide (+ dexamethasone) for lenalidomide-refractory, PI-exposed MM
- Long-term outcomes with belantamab mafodotin for relapsed/refractory MM
- Impact of COVID-19 in patients with MM
- VTE with aspirin or rivaroxaban in RVd- or KRd-treated newly diagnosed MM
- Autologous SCT in older myeloma patients
Download PDF